Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after Acute Coronary Syndrome

Thrombosis Research

Volumn 126, Issue 5, 2010, Pages

  Cuisset, Thomas ^a   Frere, Corinne ^a   Moro, Pierre Julien ^a   Quilici, Jacques ^a   Pons, Coline ^a   Gaborit, Bénédicte ^a   Camoin, Laurence ^b   Morange, Pierre Emmanuel ^a   Bonnet, Jean Louis ^a   Alessi, Marie Christine ^a  

^a TIMONE HOSPITAL   (France)

^b HÔPITAL DE LA CONCEPTION   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THROMBOXANE A2; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ACUTE CORONARY SYNDROME; ADULT; ANGIOCARDIOGRAPHY; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HYPERTENSION; LETTER; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMOKING; STATISTICAL SIGNIFICANCE; STENT THROMBOSIS; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ACUTE CORONARY SYNDROME; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RENAL INSUFFICIENCY, CHRONIC; TICLOPIDINE;

EID: 78149357797     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.08.009     Document Type: Letter

References (27)

1. M.E. Bertrand, H.J. Rupprecht, P. Urban, A.H. Gershlick, and F.T. Investigators Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS) Circulation 102 2000 624 629
2. S. Yusuf, F. Zhao, S.R. Mehta, S. Chrolavicius, G. Tognoni, and K.K. Fox Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
3. S.R. Mehta, S. Yusuf, R.J. Peters, M.E. Bertrand, B.S. Lewis, and M.K. Natarajan Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study Lancet 358 2001 527 533
4. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, F. Alfonso, C. Macaya, and T.A. Bass Variability in Individual Responsiveness to Clopidogrel Clinical Implications, Management, and Future Perspectives J Am Coll Cardiol 49 2007 1505 1516
5. S. Matetzky, B. Shenkman, V. Guetta, M. Shechter, R. Bienart, and I. Goldenberg Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 2004 3171 3175
6. T. Cuisset, C. Frere, J. Quilici, F. Barbou, P.E. Morange, and T. Hovasse High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome J Thromb Haemost 4 2006 542 549
7. P. Buonamici, R. Marcucci, A. Migliorini, G.F. Gensini, A. Santini, and R. Paniccia Impact of Platelet Reactivity After Clopidogrel Administration on Drug-Eluting Stent Thrombosis J Am Coll Cardiol 49 2007 2312 2317
8. P.J. Best, S.R. Steinhubl, P.B. Berger, A. Dasgupta, D.M. Brennan, L.A. Szczech CREDO Investigators The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial Am Heart J 155 2008 687 693
9. A. Dasgupta, S.R. Steinhubl, D.L. Bhatt, P.B. Berger, M. Shao, K.H. Mak CHARISMA Investigators Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance [CHARISMA] trial) Am J Cardiol 103 2009 1359 1363
10. S.H. Park, W. Kim, C.S. Park, W.Y. Kang, S.H. Hwang, and W. Kim A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure Am J Cardiol 104 9 Nov 1 2009 1292 1295
11. D.J. Angiolillo, E. Bernardo, D. Capodanno, D. Vivas, M. Sabaté, and J.L. Ferreiro Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy J Am Coll Cardiol 55 11 2010 1139 1146
12. P.J. Best, R. Lennon, H.H. Ting, M.R. Bell, C.S. Rihal, and D.R. Holmes The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions J Am Coll Cardiol 2002 1113 1119
13. I. Iakovou, T. Schmidt, E. Bonizzoni, L. Ge, G.M. Sangiorgi, and G. Stankovic Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents JAMA 293 2005 2126 2130
14. P.K. Kuchulakanti, W.W. Chu, R. Torguson, P. Ohlmann, S.W. Rha, and L.C. Clavijo Correlates and long term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents Circulation 113 2006 1108 1113
15. J. Machecourt, N. Danchin, J.M. Lablanche, J.M. Fauvel, J.L. Bonnet, S. Marliere EVASTENT Investigators Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry J Am Coll Cardiol 50 2007 501 508
16. U.R. Schwarz, J. Geiger, U. Walter, and M. Eigenthaler Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets-definition and detection of ticlopidine/clopidogrel effects Thromb Haemost 82 1999 1145 1152
17. A.S. Levey, J. Coresh, E. Balk, A.T. Kausz, A. Levin, M.W. Steffes National Kidney Foundation National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification Ann Intern Med 139 2003 137 147
18. D.J. Angiolillo, S.B. Shoemaker, B. Desai, H. Yuan, R.K. Charlton, and E. Bernardo Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study Circulation 115 6 Feb 13 2007 708 716
19. J.S. Hulot, G. Wuerzner, C. Bachelot-Loza, M. Azizi, A. Blanchard, and S. Peyrard Effect of an increased clopidogrel maintenance dose or lansoprazole co-administration on the antiplatelet response to clopidogrel in CYP2C19-genotyped healthy subjects J Thromb Haemost 8 3 2010 Mar 610 613
20. G. Montalescot, G. Sideris, C. Meuleman, C. Bal-dit-Sollier, N. Lellouche, and P.G. Steg A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial J Am Coll Cardiol 48 5 2006 931 938
21. T. Cuisset, C. Frere, J. Quilici, P.E. Morange, J.P. Mouret, and L. Bali Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study JACC Cardiovasc Interv. 1 6 Dec 2008 649 653
22. M. Valgimigli, G. Campo, N. de Cesare, E. Meliga, P. Vranckx, and A. Furgieri Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study Circulation 119 25 Jun 30 2009 3215 3222
23. L. Bonello, L. Camoin-Jau, S. Arques, C. Boyer, D. Panagides, and O. Wittenberg Adjusted clopidogrel loading doses according to vasodilator- stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study J Am Coll Cardiol 51 14 Apr 8 2008 1404 1411
24. S.D. Wiviott, E. Braunwald, C.H. McCabe, G. Montalescot, W. Ruzyllo, and S. Gottlieb for the TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
25. L. Wallentin, R.C. Becker, A. Budaj, C.P. Cannon, H. Emanuelsson, and C. Held Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 11 2009 1045 1057
26. K.A. Eagle, M.J. Lim, O.H. Dabbous, K.S. Pieper, R.J. Goldberg, and F. Van de Werf A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry JAMA 291 22 Jun 9 2004 2727 2733
27. G. Ducrocq, J.S. Wallace, G. Baron, P. Ravaud, M.J. Alberts, and P.W. Wilson Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis Eur Heart J 31 10 May 2010 1257 1265